Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: tringalk@mskcc.org.
² Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Comment

Kathryn R Tringale et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e218.

doi: 10.1016/S1470-2045(21)00238-2.

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: tringalk@mskcc.org.
² Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

No abstract available

Conflict of interest statement

NYL serves on the advisory board for Merck, Merck EMD, and Pfizer. KRT declares no competing interests.

Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma - Authors' reply.
Liu YP, Wen YH, Chen MY, Wen WP. Liu YP, et al. Lancet Oncol. 2021 Jun;22(6):e219. doi: 10.1016/S1470-2045(21)00270-9. Lancet Oncol. 2021. PMID: 34087129 No abstract available.

Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, Li J, Chen L, Ling L, Zhang N, Zou X, Hua YJ, Chen YM, Chen L, Lu LX, Chen MY, Wen WP. Liu YP, et al. Lancet Oncol. 2021 Mar;22(3):381-390. doi: 10.1016/S1470-2045(20)30673-2. Epub 2021 Feb 15. Lancet Oncol. 2021. PMID: 33600761 Clinical Trial.